{
  "id": 194273,
  "name": "PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)",
  "slug": "pharmaceutical-care-management-association-pcma",
  "state": "DC",
  "description": "PCMA represents pharmacy benefit managers, who administer the nation's covered Rx benefits",
  "totalSpending": 1560000,
  "filings": 24,
  "yearlySpending": [
    {
      "year": 2018,
      "income": 60000
    },
    {
      "year": 2019,
      "income": 180000
    },
    {
      "year": 2020,
      "income": 180000
    },
    {
      "year": 2021,
      "income": 280000
    },
    {
      "year": 2022,
      "income": 280000
    },
    {
      "year": 2023,
      "income": 280000
    },
    {
      "year": 2024,
      "income": 140000
    },
    {
      "year": 2025,
      "income": 160000
    }
  ],
  "firms": [
    "RED+BLUE STRATEGIES"
  ],
  "lobbyists": [
    "MELANIE NATHANSON",
    "MEGAN MARSHALL",
    "BENJAMIN KLEIN",
    "KATHRYN WISE"
  ],
  "issues": [
    "HCR",
    "MMM",
    "PHA",
    null
  ],
  "sampleDescriptions": [
    "H.R. 6 - Support for Patients and Communities Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions.\n\nS. 3120 - Helping to End Addiction and Lessen Substance Use Disorders Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions.\n\nH.R. 3528/S. 2460 - Every Prescription Conveyed Securely Act - Support for electronic prescribing of opioids to enhance patient safety. \n\nS. 2553 - Know the Lowest Price Act of 2018 - Support for the elimination of \" gag clauses\" in the Medicare Part D program.\n\nS. 2554 - Patient Right to Know Act Drug Prices Act of 2018 - Support for for the elimination of \"gag clauses\" in the private insurance market.\n\nCMS Regulations related to the Medicare Part D program and Prescription Drug Plans(PDPs).\n\nS. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. \n\nS. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars. \n\nEducation activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies. \n\nEducation activities related to the cross referencing of certain data related to Medicare Parts A, B and D.  \n\nTrump Administration's Blueprint for lowering the price of prescription medications in the United States and the role that PBMs can play in doing so.",
    "H.R. 6 - Support for Patients and Communities Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions in the Medicare program.\n\nS. 3120 - Helping to End Addiction and Lessen Substance Use Disorders Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions in the Medicare program.\n\nH.R. 3528/S. 2460 - Every Prescription Conveyed Securely Act - Support for electronic prescribing of opioids to enhance patient safety. \n\nS. 2553 - Know the Lowest Price Act of 2018 - Support for the elimination of \" gag clauses\" in the Medicare Part D program.\n\nCMS Regulations related to the Medicare Part D program and Prescription Drug Plans(PDPs).\n\nS. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. \n\nS. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars. \n\nEducation activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies. \n\nEducation activities related to the cross referencing of certain data related to Medicare Parts A, B and D.  \n\nTrump Administration's Blueprint for lowering the price of prescription medications in the United States and the role that PBMs can play in doing so.",
    "CREATES Act (S.340/ H.R. 965) - Issues related to reducing prices and increasing competition in the prescription drug marketplace.\n\nC-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained. \n\nHHS rules and regulations related  to the cost of prescription drugs, including, but not limited to,  limiting rebates in the Medicare and Medicaid prescription drug benefits.",
    "HHS rules and regulations related  to the cost of prescription drugs, including, but not limited to,  limiting rebates in the Medicare and Medicaid prescription drug benefits.",
    "S. 1895 - The Lower Health Costs Act of 2019 - Issues related to the treatment of rebates in the prescription drug arena and transparency of information and data pertaining to the buying and selling of prescription medicines. \n\nCREATES Act (S.340/ H.R. 965) - Issues related to reducing prices and increasing competition in the prescription drug marketplace.\n\nC-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained. \n\nLegislation being developed to reform Medicare Part B and D as they relate to lowering the costs of prescription medications. \n\nHHS rules and regulations related  to the cost of prescription drugs, including, but not limited to,  limiting rebates in the Medicare and Medicaid prescription drug benefits.",
    "HHS rules and regulations related  to the cost of prescription drugs, including, but not limited to,  limiting rebates in the Medicare and Medicaid prescription drug benefits. \n\nLegislative policies and reforms related to Medicare Part B and D specific to the price of prescription medications. \n\nC-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained.",
    "S. 1895 - The Lower Health Costs Act of 2019 - Issues related to the treatment of rebates in the prescription drug arena and transparency of information and data pertaining to the buying and selling of prescription medicines.\n\nCREATES Act (S.340/ H.R. 965) - Issues related to reducing prices and increasing competition in the prescription drug marketplace.\n\nC-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained. \n\nHHS rules and regulations related  to the cost of prescription drugs, including, but not limited to,  limiting rebates in the Medicare and Medicaid prescription drug benefits. \n\nPolicies related to the reform of Medicare Part B and D specific to the price of prescription medications.",
    "H.R. 1865 - Further Consolidated Appropriations Bill for FY 2020- policies focused on making prescription drugs more affordable, including the CREATES Act.\n\nH.R. 3 - The Lower Drug Costs Now Act of 2019 - Issues related to the role of PBMs in the new structure contemplated by the Act. \n\nS. 1895 - The Lower Health Costs Act of 2019 - Issues related to the treatment of rebates in the prescription drug arena and transparency of information and data pertaining to the buying and selling of prescription medicines.\n\nCREATES Act (S.340/ H.R. 965) - Issues related to reducing prices and increasing competition in the prescription drug marketplace.\n\nC-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained. \n\nHHS rules and regulations related  to the cost of prescription drugs, including, but not limited to,  limiting rebates in the Medicare and Medicaid prescription drug benefits. \n\nPolicies related to the reform of Medicare Part B and D specific to the price of prescription medications.",
    "H.R. 1865 - Further Consolidated Appropriations Bill for FY 2020- policies focused on making prescription drugs more affordable, including the CREATES Act.\n\nH.R. 3 - The Lower Drug Costs Now Act of 2019 - Issues related to the role of PBMs in the new structure contemplated by the Act. \n\nS. 1895 - The Lower Health Costs Act of 2019 - Issues related to the treatment of rebates in the prescription drug arena and transparency of information and data pertaining to the buying and selling of prescription medicines. \n\nCREATES Act (S.340/ H.R. 965) - Issues related to reducing prices and increasing competition in the prescription drug marketplace.\n\nC-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained. \n\nLegislation being developed to reform Medicare Part B and D as they relate to lowering the costs of prescription medications. \n\nHHS rules and regulations related  to the cost of prescription drugs, including, but not limited to,  limiting rebates in the Medicare and Medicaid prescription drug benefits.",
    "H.R. 3 - The Lower Drug Costs Now Act of 2019 - Issues related to the role of PBMs in the new structure contemplated by the Act. \n\nHHS rules and regulations related  to the cost of prescription drugs, including, but not limited to,  limiting rebates in the Medicare and Medicaid prescription drug benefits. \n\nLegislative policies and reforms related to Medicare Part B and D specific to the price of prescription medications. \n\nC-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained.",
    "H.R. 748 - CARES Act - Issues related to supporting the national work fighting COVID-19 and ensuring that medication is available during the COVID-19 crisis and beyond.\n\nH.R. 6201 - Families First Coronavirus Response Act -  Issues related to ensuring that the federal government is best supporting public and private healthcare programs and providers.\n\nH.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 - Issues related to supporting programs and institutions supporting during the current pandemic. \n\nHHS rules and regulations related  to the cost of prescription drugs, including, but not limited to,  limiting rebates in the Medicare and Medicaid prescription drug benefits.",
    "H.R. 1425 - The Patient Protection and Affordable Care Enhancement Act - Issues related to policies impacting the price of prescription medications in the Medicare program. \n\nH.R. 6800 - The Heroes Act - Issues related to the role of pharmacy benefits and prescription medications in response to the COVID -19 pandemic in the Medicare and Medicaid programs.\n\n\nH.R. 748 - CARES Act -Implementation-  Issues related to supporting the national work fighting COVID-19 and ensuring that medication is available during the COVID-19 crisis and beyond.\n\nH.R. 6201 - Families First Coronavirus Response Act - Implementation-  Issues related to ensuring that the federal government is best supporting public and private healthcare programs and providers.\n\nH.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 - Implementation - Issues related to supporting programs and institutions supporting during the current pandemic. \n\nHHS rules and regulations related  to the cost of prescription drugs, including, but not limited to,  limiting rebates in the Medicare and Medicaid prescription drug benefits.",
    "H.R. 1425 - The Patient Protection and Affordable Care Enhancement Act - Issues related to policies impacting the price of prescription medications. \n\nH.R. 6800 - The Heroes Act - Issues related to the role of pharmacy benefits and prescription medications in response to the COVID -19 pandemic.\n\nH.R. 748 - CARES Act - Implementation -  Issues related to supporting the national work fighting COVID-19 and ensuring that medication is available during the COVID-19 crisis and beyond.\n\nH.R. 6201 - Families First Coronavirus Response Act - Implementation-  Issues related to ensuring that the federal government is best supporting public and private healthcare programs and providers.\n\nH.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 - Implementation - Issues related to supporting programs and institutions supporting during the current pandemic. \n\nHHS rules and regulations related  to the cost of prescription drugs, including, but not limited to,  limiting rebates in the Medicare and Medicaid prescription drug benefits.",
    "H.R. 1425 - The Patient Protection and Affordable Care Enhancement Act - Issues related to policies impacting the price of prescription medications. \n\nH.R. 6800 - The Heroes Act - Issues related to the role of pharmacy benefits and prescription medications in response to the COVID -19 pandemic.\n\nH.R. 748 - CARES Act -Implementation- Issues related to supporting the national work fighting COVID-19 and ensuring that medication is available during the COVID-19 crisis and beyond.\n\nH.R. 6201 - Families First Coronavirus Response Act - Implementation- Issues related to ensuring that the federal government is best supporting public and private healthcare programs and providers.\n\nH.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 -Implementation- Issues related to supporting programs and institutions supporting during the current pandemic. \n\nHHS rules and regulations related  to the cost of prescription drugs, including, but not limited to,  limiting rebates in the Medicare and Medicaid prescription drug benefits.",
    "Executive Orders and Regulations related to pharmacy issues including the creation of an international price index, a Medicare drug discount card and the Medicare rebate rule.\n\nPL 116-260/H.R. 133- Consolidated Appropriations Act of 2021 - Issues related to pharmacy benefit managers' roles and tools to negotiate drug prices in the Medicare Part D. Medicaid and commercial markets.\n\nH.R. 748 - CARES Act - Implementation -  Issues related to supporting the national work fighting COVID-19 and ensuring that medication is available during the COVID-19 crisis and beyond.\n\nH.R. 6201 - Families First Coronavirus Response Act - Implementation-  Issues related to ensuring that the federal government is best supporting public and private healthcare programs and providers.\n\nH.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 - Implementation - Issues related to supporting programs and institutions supporting during the current pandemic. \n\nHHS rules and regulations related  to the cost of prescription drugs, including, but not limited to,  limiting rebates in the Medicare and Medicaid prescription drug benefits.",
    "Executive Orders and Regulations related to pharmacy issues including the creation of a Medicare drug discount card and the Medicare rebate rule.\n\nPL 116-260/H.R. 133- Consolidated Appropriations Act of 2021 - Issues related to pharmacy benefit managers' roles and tools to negotiate drug prices in the Medicare Part D. Medicaid and commercial markets.\n\nH.R. 748 - CARES Act -Implementation-  Issues related to supporting the national work fighting COVID-19 and ensuring that medication is available during the COVID-19 crisis and beyond.\n\nH.R. 6201 - Families First Coronavirus Response Act - Implementation-  Issues related to ensuring that the federal government is best supporting public and private healthcare programs and providers.\n\nH.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 - Implementation - Issues related to supporting programs and institutions supporting during the current pandemic. \n\nHHS rules and regulations related  to the cost of prescription drugs, including, but not limited to,  limiting rebates in the Medicare and Medicaid prescription drug benefits.",
    "Executive Orders and Regulations related to pharmacy issues including the creation of an international price index, a Medicare drug discount card and the Medicare rebate rule.\n\nPL 116-260/H.R. 133- Consolidated Appropriations Act of 2021 - Issues related to pharmacy benefit managers' roles and tools to negotiate drug prices in the Medicare Part D. Medicaid and commercial markets.\n\nH.R. 748 - CARES Act -Implementation- Issues related to supporting the national work fighting COVID-19 and ensuring that medication is available during the COVID-19 crisis and beyond.\n\nH.R. 6201 - Families First Coronavirus Response Act - Implementation- Issues related to ensuring that the federal government is best supporting public and private healthcare programs and providers.\n\nH.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 -Implementation- Issues related to supporting programs and institutions supporting during the current pandemic. \n\nHHS rules and regulations related  to the cost of prescription drugs, including, but not limited to,  limiting rebates in the Medicare and Medicaid prescription drug benefits.",
    "PL 177-2 - The American Rescue Plan Act - Issues related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.\n\nIssues related to Trump-era rules and regulations regarding Medicare rebate policies and PBM transparency.",
    "PL 117-2 - The American Rescue Plan Act - Issues related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.\n\nIssues related to Trump-era rules and regulations regarding Medicare rebate policies and PBM transparency.",
    "PL 117-2 - The American Rescue Plan Act Implementation- Issues related to policies that increase access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.\n\nIssues related to Trump-era rules and regulations regarding Medicare rebate policies and PBM transparency."
  ],
  "years": [
    2018,
    2019,
    2020,
    2021,
    2022,
    2023,
    2024,
    2025
  ],
  "growthRate": 167,
  "trajectory": "exploding",
  "yearsActive": 8,
  "avgAnnualSpending": 195000,
  "peakYear": 2021,
  "lobbyistCount": 4,
  "firmCount": 1,
  "issueCount": 3,
  "industry": "healthcare"
}